Reviewing ProQR Therapeutics N.V. (PRQR)’s and CTI BioPharma Corp. (NASDAQ:CTIC)’s results

ProQR Therapeutics N.V. (NASDAQ:PRQR) and CTI BioPharma Corp. (NASDAQ:CTIC), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics N.V. 11 0.00 N/A -1.23 0.00
CTI BioPharma Corp. 1 3.18 N/A -0.62 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 shows us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics N.V. 0.00% -53.9% -43.8%
CTI BioPharma Corp. 0.00% -61.3% -40.4%

Risk & Volatility

ProQR Therapeutics N.V. has a 0.09 beta, while its volatility is 91.00%, thus making it less volatile than S&P 500. CTI BioPharma Corp. has a 1.55 beta and it is 55.00% more volatile than S&P 500.

Insider and Institutional Ownership

ProQR Therapeutics N.V. and CTI BioPharma Corp. has shares owned by institutional investors as follows: 68.5% and 53.9%. ProQR Therapeutics N.V.’s share owned by insiders are 20%. Comparatively, 0.1% are CTI BioPharma Corp.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ProQR Therapeutics N.V. 5.15% -6.99% -20.18% -41.23% 32.03% -44.36%
CTI BioPharma Corp. 0.72% -12.54% -24.64% -37.44% -67.32% -0.22%

For the past year ProQR Therapeutics N.V. was more bearish than CTI BioPharma Corp.


CTI BioPharma Corp. beats ProQR Therapeutics N.V. on 4 of the 7 factors.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.